| Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. | |
| | |
MedLine Citation:
|
PMID: 22315277 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Neonates and children differ from adults in physiology, pharmacologic responses to drugs, epidemiology, and long-term consequences of thrombosis. This guideline addresses optimal strategies for the management of thrombosis in neonates and children. METHODS: The methods of this guideline follow those described in the Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. RESULTS: We suggest that where possible, pediatric hematologists with experience in thromboembolism manage pediatric patients with thromboembolism (Grade 2C). When this is not possible, we suggest a combination of a neonatologist/pediatrician and adult hematologist supported by consultation with an experienced pediatric hematologist (Grade 2C). We suggest that therapeutic unfractionated heparin in children is titrated to achieve a target anti-Xa range of 0.35 to 0.7 units/mL or an activated partial thromboplastin time range that correlates to this anti-Xa range or to a protamine titration range of 0.2 to 0.4 units/mL (Grade 2C). For neonates and children receiving either daily or bid therapeutic low-molecular-weight heparin, we suggest that the drug be monitored to a target range of 0.5 to 1.0 units/mL in a sample taken 4 to 6 h after subcutaneous injection or, alternatively, 0.5 to 0.8 units/mL in a sample taken 2 to 6 h after subcutaneous injection (Grade 2C). CONCLUSIONS: The evidence supporting most recommendations for antithrombotic therapy in neonates and children remains weak. Studies addressing appropriate drug target ranges and monitoring requirements are urgently required in addition to site- and clinical situation-specific thrombosis management strategies. |
| | |
Authors:
|
Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely; |
Related Documents
:
|
22272447 - Meningococcal disease in children: a clinical review. 22646757 - Risk factors in the occurrence of molar-incisor hypomineralization amongst a group of i... 22741947 - Caregiver expectations of clinicians during the asthma diagnostic process in young chil... 22317277 - Ergonomics content in the physical education teacher's guide in rwanda. 9190557 - Use of codeine- and dextromethorphan-containing cough remedies in children. american ac... 16159527 - Broad-spectrum efficacy of zonisamide at 12 months in children with intractable epilepsy. |
Publication Detail:
|
Type: Journal Article; Practice Guideline |
Journal Detail:
|
Title: Chest Volume: 141 ISSN: 1931-3543 ISO Abbreviation: Chest Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-02-08 Completed Date: 2012-04-13 Revised Date: 2013-04-08 |
Medline Journal Info:
|
Nlm Unique ID: 0231335 Medline TA: Chest Country: United States |
Other Details:
|
Languages: eng Pagination: e737S-801S Citation Subset: AIM; IM |
Affiliation:
|
Haematology Department, The Royal Children's Hospital, Department of Paediatrics, The University of Melbourne, Murdoch Children's Research Institute, Melbourne, VIC, Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticoagulants
/
administration & dosage,
adverse effects Blood Coagulation Tests Cardiac Catheterization Child Child, Preschool Cooperative Behavior Dose-Response Relationship, Drug Drug Administration Schedule Evidence-Based Medicine* Factor Xa / antagonists & inhibitors Fibrinolytic Agents / administration & dosage*, adverse effects Hemorrhage / blood, chemically induced, prevention & control Heparin / administration & dosage, adverse effects Heparin, Low-Molecular-Weight / administration & dosage, adverse effects Humans Infant, Newborn Interdisciplinary Communication Platelet Aggregation Inhibitors / administration & dosage, adverse effects Recurrence / prevention & control Renal Veins Risk Factors Societies, Medical* Thrombosis / blood, drug therapy*, etiology, prevention & control* Upper Extremity Deep Vein Thrombosis / blood, drug therapy, prevention & control Vitamin K / antagonists & inhibitors |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Fibrinolytic Agents; 0/Heparin, Low-Molecular-Weight; 0/Platelet Aggregation Inhibitors; 12001-79-5/Vitamin K; 9005-49-6/Heparin; EC 3.4.21.6/Factor Xa |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of ...
Next Document: Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of...